Welcome to our dedicated page for Oaktree Acquisition III Life Sciences SEC filings (Ticker: OACCU), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Oaktree Acquisition III Life Sciences's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Oaktree Acquisition III Life Sciences's regulatory disclosures and financial reporting.
Oaktree Acquisition Corp. III Life Sciences files its Annual Report outlining its structure and strategy as a Cayman Islands–incorporated, healthcare-focused special purpose acquisition company. It is a blank check company formed in June 2024 to complete an initial business combination.
The company plans to merge with biopharma, medical device, diagnostics or specialized healthcare services businesses in North America, the UK and Western Europe, leveraging its affiliation with Oaktree, which had $223 billion in assets under management as of December 31, 2025. Oaktree’s life sciences platform has committed about $6.2 billion across 54 investments since 2013.
As of December 31, 2025, the SPAC had $201,563,532 available to fund a deal and must complete a business combination within 24 months of its IPO, with potential extensions up to 36 months. The report details sponsor economics, potential conflicts of interest, warrant and share lock-up terms, and the requirement that any target (or targets) have an aggregate fair market value of at least 80% of net assets held in trust at signing.
Oaktree Acquisition Corp I-A received an updated ownership report from Barclays PLC, which filed an amended Schedule 13G/A as of December 31, 2025. Barclays reported beneficial ownership of 861,625 common shares, representing 4.35% of the class.
Barclays reported sole voting and sole dispositive power over all 861,625 shares, with no shared voting or dispositive power. The filing states that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the company.